Jennifer Yeh

TL;DR: It is shown, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations.

TL;DR: It is shown that the MAPK pathway inhibits ephrin-A1 expression, and the ligand expression inhibits EphA2 levels contributing to the receptor-ligand reciprocal expression pattern in these cell lines, suggesting that an escape from the negative effects of this interaction may be important in the development of cancer.

TL;DR: It is shown, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations.

TL;DR: A recent study as discussed by the authors showed that topical imiquimod is a potent modulator of innate and adaptive immune response by binding to Toll-like receptors 7 and 8 on antigen-presenting cells, leading to enhanced T-cell priming, and stimulating tumor-specific Tcell responses.

TL;DR: The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma as mentioned in this paper .